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Background: Activin A released from epicardial adipose tissue has been linked to contractile dysfunction and insulin
resistance in cardiomyocytes. This study investigated the role of activin A in clinical diabetic cardiomyopathy by
assessing whether circulating activin A levels associate with cardiometabolic parameters in men with uncomplicated
type 2 diabetes (T2D), and the effects of treatment with pioglitazone versus metformin on these associations.
Methods: Seventy-eight men with uncomplicated T2D and fourteen healthy men with comparable age were
included, in this randomized, double-blind, active comparator intervention study. All T2D men were on glimipiride
monotherapy, and randomized to a 24-week intervention with either pioglitazone or metformin. Cardiac
dimensions and -function were measured using magnetic resonance imaging, whilst myocardial glucose
metabolism (MMRglu) was determined using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography
during a hyperinsulinemic-euglycemic clamp.
Results: Circulating activin A levels were comparable in T2D men and controls. Activin A levels were
independently inversely associated with MMRglu, and positively with left ventricular mass/volume (LVMV)-ratio in
T2D men. Intervention with metformin decreased activin A levels, whereas pioglitazone did not alter activin A
levels. The changes in plasma activin A levels were not correlated with the changes in MMRglu following either
pioglitazone or metformin treatment. A borderline significant correlation (p = 0.051) of changes in plasma activin A
levels and changes in LVMV-ratio was observed after pioglitazone treatment.
Conclusions: Circulating activin A levels are associated with impaired myocardial glucose metabolism and
high LVMV-ratio in patients with uncomplicated T2D, reflecting a potential detrimental role in early human
diabetic cardiomyopathy.
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Diabetic cardiomyopathy is a multifactorial condition
characterized by an impaired cardiac function independent
of coronary artery disease or hypertension [1]. Changes
in myocardial substrate metabolism are described to
contribute to its pathogenesis. Subtle defects in cardiac
structure and function can be detected before the presence
of clinically evident cardiac disease [2,3]. These defects
are amendable to therapeutic interventions since benefi-
cial effects of pioglitazone on myocardial glucose me-
tabolism and diastolic function in patients with type 2
diabetes (T2D) have been reported [4].
Epicardial adipose tissue (EAT) is a visceral fat depot
directly surrounding the myocardium [5]. Emerging evi-
dence shows that factors secreted by EAT exert paracrine
effects on cardiac metabolism and contractile function,
hence, with the potential to contribute to the develop-
ment of cardiovascular disease [5]. Especially activin A is
of interest in this context. An enhanced release of activin
A from EAT of patients with T2D impairs cardiomyocyte
function in vitro [6]. Furthermore, the fibrotic potential
of the EAT secretome has been ascribed to activin A [7].
This study aimed at investigating whether activin A im-
pacts on the pathophysiology of diabetic cardiomyopathy.
Therefore, we determined circulating activin A levels in
men with uncomplicated T2D and healthy men of com-
parable age, evaluated the association of activin A levels
with cardiac function and –metabolism, and examined the




Circulating activin A levels were determined in fasting
plasma samples from participants of the previously de-
scribed PIRAMID (Pioglitazone Influence on tRiglyceride
Accumulation in the Myocardium in Diabetes) study [4,8].
This study included 78 T2D men, aged 45–65 years, with
an HbA1c of 6.5 – 8.5 %, a body mass index (BMI) of 25–
32 kg/m2, and a sitting blood pressure (BP) less than
150/85 mmHg. Furthermore, we included 14 healthy men
of comparable age with normal glucose metabolism as
determined by a 75-g oral glucose tolerance test. The
T2D men were randomized in this 24-week randomized,
double-blind, double-dummy with active comparator trial,
to pioglitazone (15 mg once daily, titrated to 30 mg once
daily after 2 weeks) or metformin (500 mg twice daily,
titrated to 1000 mg twice daily) and matching placebo.
The PIRAMID study was conducted at two university
medical hospitals in the Netherlands (Leiden University
Medical Center, Leiden, and VU University Medical Center,
Amsterdam), and approved by the medical ethics com-
mittee of both centers. This study was performed in full
compliance with the Declaration of Helsinki.Cardiac magnetic resonance imaging (MRI)
All participants underwent MRI scanning on a 1.5 Tesla
whole-body MR scanner (Gyroscan ACS/NT15; Philips,
Best, the Netherlands) after an overnight fast. Technical
procedures were performed as described earlier [4,9].
Images were analyzed quantitatively with dedicated soft-
ware (MASS and FLOW, Medis, Leiden, the Netherlands).
During MRI, BP and heart rate (HR) were measured. Left
ventricular (LV) mass/volume ratio (LVMV-ratio) was
calculated as the ratio between LV enddiastolic mass
and LV enddiastolic volume.
Positron emission tomography (PET) protocol
All PET examinations were performed using an ECAT
EXACT HR+ scanner (Siemens/CTI, Knoxville, Tennessee).
Myocardial metabolic rate of glucose (MMRglu) was
measured during a hyperinsulinemic-euglycemic clamp
procedure [10], using [18F]-2-fluoro-2-deoxy-D-glucose
([18F]-FDG). After injection of 185 MBq [18F]-FDG, a
60-min dynamic emission scan was acquired.
PET image analysis
PET data were quantitatively reconstructed using filtered
back projection after all appropriate corrections. To
generate myocardial time-activity curves, regions of inter-
est were defined on resliced LV short-axis (summed)
[18F]-FDG images and subsequently projected onto the
dynamic images. Regions of interest were drawn as pre-
viously described [11], and grouped for further analysis.
A separate aorta ascendance region of interest was
defined to generate an 18F-FDG image-derived input
function. MMRglu was calculated by multiplying the net
rate of influx constant of 18F-FDG, Ki, by the mean plasma
glucose concentration. Ki was determined using Patlak
graphic analysis [12].
Biochemical analysis
Plasma activin A levels were determined using an Enzyme
Linked Immuno Sorbent Assay (R&D systems, Minneapolis,
MN, USA). The lower detection limit of the assay was
3.67 pg/mL. The intra- and interassay coefficients of vari-
ation were 4.4% and 5.0%, respectively. This assay shows
no significant cross-reactivity with activin B and activin C,
and 0.45% cross-reactivity with Activin AB, and measures
both free and follistatin-bound activin A dimers.
Statistical analysis
Data are expressed as mean ± standard deviation of the
mean or median (interquartile range) when non-normally
distributed. Group differences were determined using stu-
dents t-test for normal distributed data, and Mann–Whitney
U-test for skewed distributed data. Correlation coefficients
were calculated using Pearson’s correlation. Ln-transformed
data were used in case of skewed distributions. Linearity
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histograms and scatter plots. Additional potential con-
founders were investigated by adding age, BMI,
systolic BP (SBP), diastolic BP (DBP), HR, fasting glu-
cose, and fasting triglyceride levels in the multivariate
analysis of activin A with LVMV-ratio and aortic
pulse wave velocity (PWV). Next, age, BMI, SBP, DBP,
HR, fasting glucose, insulin, and triglyceride levels,
and M-value for insulin sensitivity were added in the
multivariate analysis for associations of activin A with
MMRglu. Variables that changed regression coeffi-
cients by more than 10% were included in the
adjusted model. Between-group comparisons were
performed using ANCOVA with adjustments for
intervention group and baseline values. Within-group
changes from baseline were assessed using independ-
ent paired t–test for normal distributed data and
Wilcoxon signed-ranked test for skewed distributed
data. Statistical analyses were performed using SPSS
software version 20.0 (IBM corporation, New York,
USA). A value of P < 0.05 was considered as statisti-
cally significant.
Results
Plasma activin A levels in T2D men versus controls and its
relationship with metabolic and cardiac parameters
The anthropometric and cardiometabolic variables of
the participants were described previously [13]. Im-
portantly, T2D men had impaired metabolic control
and LV diastolic dysfunction [13] (Additional file 1:Figure 1 Plasma activin A levels in men with uncomplicated type 2 d
plasma activin A levels in 78 type 2 diabetic (T2D) men and 14 healthy con
Mann–Whitney U-test. Regression analyses showed significant inverse corre
glucose for all subjects, T2D men and control (Co) subjects (MMRglu; B), and
C), and aortic pulse wave velocity (PWV; D) in T2D men (black dots with black
Grey lines represent pooled regression lines.Table S1). Median activin A levels were comparable
between T2D men and controls (293 versus 315 pg/
mL, p = 0.42; Figure 1A). Univariate regression ana-
lyses (Additional file 2: Table S2) showed inverse
correlations between activin A levels and MMRglu
(r = −0.450, p < 0.001; Figure 1B) and positive
correlations with age (r = 0.232, p = 0.04), diabetes
duration (r = 0.236, p = 0.04), triglycerides (r = 0.258,
p = 0.02), SBP (r = 0.277, p = 0.01), LVMV-ratio
(r = 0.353, p = 0.002; Figure 1C), and PWV (r = 0.238,
p = 0.04; Figure 1D) in T2D. Notably, plasma activin
A levels were not significantly correlated with fasting
glucose levels (r = −0.210, p = 0.07), fasting insulin
levels (r = 0.154, p = 0.18), or M-value (r = −0.190,
p = 0.11), nor with diastolic function parameters
(all p > 0.05; Additional file 2: Table S2). In multi-
variate analysis of the T2D patients, the association
of activin A levels with MMRglu was not affected by
adjustment for M-value (β = −0.373, p = 0.001). Age,
SBP, DBP, BMI, as well as fasting glucose, insulin, or
triglyceride levels did not change the regression
coefficient. The association of activin A levels with
LVMV-ratio remained significant after adjustment for
SBP (β = 0.276, p = 0.02). However, age and SBP
were confounding factors in the association of
activin A levels with PWV (β = 0.151, p = 0.13).
Other variables as DBP, HR, BMI, fasting glucose, or
triglyceride levels did not change the regression
coefficients of the association between activin A
levels and either LVMV-ratio or PWV.iabetes versus controls. (A) Whisker plots (median, min – max) of
trol men. Differences in plasma activin A levels were analyzed using a
lation of plasma activin A levels with myocardial metabolic rate of
positive correlations with left ventricular mass/volume ratio (LVMV-ratio;
regression line) and controls (white dots with dashed regression line).
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A levels
Previously, we reported that treatment with pioglitazone
or metformin improved glycemic control in both groups
[4]. Furthermore, an improvement in diastolic function
and myocardial glucose metabolism after pioglitazone
treatment was observed as compared to metformin
treatment, together with a decrease in LVMV-ratio only
after pioglitazone treatment [4]. Neither pioglitazone
nor metformin impacted on PWV (Additional file 3:
Table S3). Treatment with pioglitazone did not change
activin A levels (293 to 302 pg/mL, p = 0.13; Figure 2A).
After metformin, activin A levels decreased (293 to 261
pg/mL, p = 0.002; Figure 2A). Between-group analysis
showed a decrease of activin A levels after metformin
versus pioglitazone, with adjustment for baseline activin
A levels (p < 0.001; Figure 2A). Changes in activin A
levels were correlated neither with changes in MMRglu
(Figure 2B) nor with changes in PWV (Figure 2D) fol-
lowing treatment with either pioglitazone or metfor-
min. A borderline significant correlation of changes
in activin A levels and changes in LVMV-ratio was
observed after pioglitazone (r = 0.338, p = 0.051), but not
after metformin treatment (r = 0.048, p = 0.78; Figure 2C).
Discussion
This study shows that circulating plasma activin A
levels in T2D men without cardiovascular complica-
tions associate with impaired myocardial glucoseFigure 2 Effects of 24-week pioglitazone versus metformin on activin
baseline (BL, light grey) and at 24-weeks follow-up (FU, dark grey) after inte
with uncomplicated type 2 diabetes (T2D). Differences in plasma activin A
Wilcoxon matched-pair signed-rank test, between-group differences were p
intervention group and baseline values. Pearson correlation analysis showe
MMRglu after either pioglitazone (black dots, black regression line) or metf
significant positive correlation was seen between changes in activin A leve
pioglitazone, not after metformin (C). Changes in activin A levels were not
pioglitazone (black dots, black regression line) or metformin (white squaresmetabolism, independent of M-value. Furthermore, we
observed a positive association with the LVMV-ratio.
Metformin treatment decreased activin A levels, while
pioglitazone had no effect. Furthermore, in patients
treated with pioglitazone, changes in plasma activin A
levels were borderline significantly correlated with changes
observed in LVMV-ratio. There was no association
between changes in plasma activin A and myocardial
glucose metabolism after either pioglitazone or metformin
treatment. These results suggest an involvement of activin
A in the pathogenesis of early cardiac derangements
in T2D.
Importantly, the pathogenesis of diabetic cardiomyop-
athy is not yet completely unraveled. It has been proposed
that myocardial dysfunction in patients with T2D is related
to depletion of endothelial progenitor cells and increased
oxidative stress [14]. Others demonstrated that early T2D
is associated with an increase in the sarco/endoplasmic
reticulum Ca2+-ATPase (SERCA) / phospholamban-ratio
and that insulin directly stimulates SERCA expression
and relaxation velocity [15]. Finally, circulating levels of
osteoprotegerin and adiponectin were found to associate
with cardiac abnormalities in men with uncomplicated
T2D [16]. The present study identifies activin A as
additional potential factor contributing to the pathogenesis
of myocardial dysfunction in diabetic cardiomyopathy.
Levels of circulating activin A were in the same range
as other clinical studies [17-19]. Although one study
reported that high activin A levels associated withA levels in type 2 diabetic men. (A) Plasma activin A levels at
rvention with pioglitazone (dots) versus metformin (squares) in men
levels at BL and FU in each intervention group were analyzed using
erformed using linear regression analysis with adjustments for
d that changes in activin A levels were not related to changes in
ormin (white squares, dashed regression line; B). A marginally
ls and changes in left ventricular mass/volume ratio (LVMV-ratio) after
correlated with changes in pulse wave velocity after either
, dashed regression line; D).
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infarction though without known T2D [20], we as well
as others did not find altered activin A levels between
patients with (uncomplicated) T2D and controls [19,21,22].
Nevertheless, activin A levels tended to be higher in
patients with cardiovascular disease [17]. In patients
with stable and unstable angina, levels of activin A
were elevated as compared to healthy controls [17]. Also
in T2D patients with coronary artery disease higher levels
of activin A were found as compared to T2D patients
without coronary artery disease [19]. Finally, in heart
failure patients, increased activin A levels were demon-
strated as compared to healthy controls [18,19].
Some studies have reported beneficial effects of activin
A. Activin A is a dimeric protein consisting of two inhibin
βA monomers linked by a single disulfide bond. In mice,
maternal diabetes induces cardiac malformations in the
embryos by downregulation of inhibin βA, and in associ-
ation decreased activation of the post-receptor signaling
components Smad2 and/or Smad3 [23,24]. Furthermore,
Zhao et al. demonstrated that activin A was able to rescue
myocardial cell proliferation and endocardial cell migra-
tion in mouse embryonic hearts which was suppressed by
maternal diabetes [25]. Other investigators have proposed
that activin A could have beneficial effects on inflamma-
tion and atherogenesis, and that high activin A levels re-
flect a counteracting anti-inflammatory and anti-oxidative
response [19,20]. The present findings do not support
this, but are corroborated by our earlier studies in which
we showed that activin A derived from EAT from T2D
patients impairs cardiomyocyte insulin sensitivity by
inhibiting the insulin-mediated phosphorylation of Akt
through induction of microRNA-143 [6,26].
The association of activin A with LVMV-ratio indicates
that this factor is involved in early myocardial remodeling
in T2D as well, as LVMV-ratio is one of the features of
isolated LV diastolic dysfunction [7,13,27]. Importantly,
this is supported by our results showing that changes in
activin A levels after only pioglitazone were borderline
positively correlated with changes in LVMV-ratio.
Although an in vitro study on monocytes reported no
effect of pioglitazone on activin A release [21], it should
be noted that the key effector for pioglitazone, PPARγ,
is predominantly expressed in adipose tissue. Further-
more, expression is activin A is ubiquitous [6,7,28,29],
and high expression levels have been reported in human
adipocyte progenitor cells [29]. During differentiation
into adipocytes activin A expression is downregulated,
and inhibition of the activin A signaling has been found
to promote human adipogenesis [29]. Based on these
observations, one may speculate that pioglitazone im-
proves adipocyte differentiation and adipose tissue qual-
ity, thereby lowering activin A production by mature
adipocytes. Interestingly, a recent report directly linkedactivin A released from EAT to the development of car-
diac fibrosis [7]. This raises the possibility that the reduc-
tion of the LVMV-ratio in pioglitazone-treated patients
may result from local effects of pioglitazone on epicardial
adipocytes rather than a systemic effect on circulating
activin A levels. Accordingly, we could recently demon-
strate that activin A release is increased in EAT from
patients with T2D [6,26]. This fat depot is not separated
by a fascia from the underlying tissue and shares the
blood supply with the myocardium. Consequently, activin
A released from EAT can directly affect cardiac function
in a paracrine fashion.
The current findings do not completely exclude the
possibility that the effects of pioglitazone on the LVMV-
ratio result from an improved left ventricular diastolic
function in this treatment group. In support of this
notion is that metformin treatment did not affect car-
diac function, including the LVMV-ratio [4], despite
lowering circulating activin A levels. An in vitro study
on monocytes also reported a downregulation of activin A
release following metformin exposure [21]. However, the
absence of a beneficial effect of metformin on determi-
nants of left ventricular diastolic function may prevent
beneficial effects on left ventricular hypertrophy despite
lower circulating activin A levels.
Another issue that should be considered is that the
expression and release of activin A is not confined to
EAT. Rather activin A is expressed by a large number of
cells and tissues, including (epicardial) adipose tissue
[6,7,28,29]. Because the circulating levels of activin A
were not different between controls and patients with
T2D, it seems likely that the amount of activin A found
in the circulation is also derived from these other sources.
Nevertheless, both our previous in vitro studies [6,26] and
the present clinical study support the notion that activin
A participates in the development of cardiac abnormalities
in patients with T2D.
Limitations
This study has several limitations. First, the number of
control subjects examined in this study was relatively
small. Consequently, additional studies remain required
to confirm the lack of association between activin A and
cardiometabolic parameters in subjects without T2D.
Second, our study was conducted in males. Although
this may limit generalization of our findings, it should
be noted that multiple studies showed that gender is not
a confounding factor for levels of activin A levels in the
circulation [18,19,22,30,31].
Conclusions
This is the first report showing independent relationships
of plasma activin A levels with both impaired myocardial
glucose metabolism and increased LVMV-ratios in T2D
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of diabetic cardiomyopathy is not fully understood, the
present data provide evidence for a potential role of activin
A in the development of early diabetic cardiomyopathy.
However, the data should be interpreted with caution, as
further studies are warranted to identify the exact role of
activin A in cardiac remodeling in diabetic cardiomyopathy.
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